Table 1 Respondent characteristics by method of presentation
Respondent characteristics | All respondents (n = 35,823) | Method of presentation | |||
|---|---|---|---|---|---|
PSA-detected (n = 11,210) | Symptomatic (n = 21,378) | Other (n = 1821) | Unknown (n = 1414) | ||
Age at diagnosis | |||||
  < 54 | 3.9% | 4.0% | 3.7% | 5.7% | 3.5% |
 55-64 | 23.8% | 24.4% | 23.7% | 26.1% | 17.5% |
 65-74 | 47.4% | 48.9% | 47.0% | 46.1% | 44.7% |
 75+ | 24.9% | 22.7% | 25.6% | 22.1% | 34.4% |
Stage | |||||
 I/II | 64.0% | 71.2% | 60.1% | 65.3% | 64.4% |
 III | 23.3% | 22.0% | 24.3% | 20.7% | 21.6% |
 IV | 12.7% | 6.7% | 15.6% | 14.0% | 14.0% |
Gleason score | |||||
 2-6 | 29.0% | 31.1% | 27.7% | 29.5% | 30.8% |
 7 | 47.3% | 51.4% | 45.3% | 48.1% | 45.0% |
 8-10 | 23.7% | 17.5% | 27.0% | 22.3% | 24.2% |
Treatment type a | |||||
 Any surgery | 30.0% | 31.9% | 28.9% | 31.8% | 28.9% |
 Any EBRT | 38.9% | 37.5% | 40.4% | 35.6% | 32.5% |
 Any brachytherapy | 8.6% | 10.7% | 7.6% | 7.7% | 9.2% |
 Any ADT | 43.0% | 37.0% | 46.6% | 42.3% | 37.6% |
 Any systemic | 5.0% | 2.5% | 6.2% | 5.7% | 4.9% |
 Any other | 14.0% | 15.0% | 13.3% | 12.4% | 18.5% |
 Monitoring only | 16.8% | 18.1% | 15.9% | 17.3% | 20.2% |